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Abstract
Background: Protein kinases are key regulators of cellular processes (such as proliferation, apoptosis and invasion) that are
often deregulated in human cancers. Accordingly, kinase genes have been the first to be systematically analyzed in human
tumors leading to the discovery that many oncogenes correspond to mutated kinases. In most cases the genetic alterations
translate in constitutively active kinase proteins, which are amenable of therapeutic targeting. Tumours of the pancreas are
aggressive neoplasms for which no effective therapeutic strategy is currently available.
Methodology/Principal Findings: We conducted a DNA-sequence analysis of a selected set of 35 kinase genes in a panel of
52 pancreatic exocrine neoplasms, including 36 pancreatic ductal adenocarcinoma, and 16 ampulla of Vater cancer. Among
other changes we found somatic mutations in ATM, EGFR, EPHA3, EPHB2, and KIT, none of which was previously described in
cancers.
Conclusions/Significance: Although the alterations identified require further experimental evaluation, the localization
within defined protein domains indicates functional relevance for most of them. Some of the mutated genes, including the
tyrosine kinases EPHA3 and EPHB2, are clearly amenable to pharmacological intervention and could represent novel
therapeutic targets for these incurable cancers.
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Introduction
Protein kinases are key regulators of different and complex
cellular processes such as cell cycle progression, differentiation,
apoptosis and invasion [1–4]. The protein kinase complement
(defined as ‘‘kinome’’) represents a significant fraction of the human
genome, and recently Manning et al. organized it into a dendogram
containing nine broad groups of genes [5]. Alterations in a kinase
gene can lead to an aberrant protein activity, which may have a role
in cancer initiation and progression [6,7]. These alterations,
including point mutations and deletions in conserved domains,
often result in constitutively activated kinases, which are potential
therapeutic targets for cancer treatment. Indeed, there are several
small molecule inhibitors currently in use or being evaluated in
clinicaltrials[8–10].Mutationsinakinasegenemayalsoresultinits
inactivation, as for genes involved in the maintenance of genome
stability [11,12] or controlling cell-cell communication [13]. In
recent years, extensive sequence analysis of tumour genomes and
particularly of kinase gene family has been conducted in different
epithelial tumours leading to the identification of different somatic
mutations [14–22]. These works point to a subset of kinase genes
with known or potential relationship with solid tumour develop-
ment, as they display a relatively high frequency of mutations.
To determine the presence of mutations potentially relevant as
therapeutic targets, we conducted a DNA-sequence analysis of a
selected set of kinase genes in a panel of two different pancreatic
neoplasms, including pancreatic ductal adenocarcinoma (PDAC),
and ampulla of Vater cancer (AVC). For these tumour types no
effective therapeutic agents are currently available [23,24]. For
example, PDAC is highly aggressive and resistant to conventional
and targeted therapeutic agents, resulting in a dismal 5-year
survival rate of 3% to 5% [24]. Here we present the mutational
profile of 35 genes belonging to the kinase gene families in PDAC
and AVC. Specifically we found non-synonymous mutations in the
following genes: ATM, BRAF, EGFR, EPHA3, EPHB2, ERBB2,
FGFR2, KIT, and PIK3CA. Among these changes, there were both
well-characterized mutations and mutations affecting aminoacid
not previously found to be mutated in human cancers.
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Ethics Statement
All research involving human participants was approved by the
University and Hospital Trust’s Institutional Board. Informed
consent was obtained in writing from living patients or relatives for
all tissues used in this study.
Samples
The panel of 52 pancreatic cancer samples was obtained from
the tumour bank maintained by the Department of Pathology,
Section of Anatomic Pathology, University of Verona (Verona,
Italy), except for six of pancreatic adenocarcinoma samples
provided by Dr. Daniela Campani (University of Pisa). Samples
were collected according to the ethical requirements and
regulations of the review boards of both the University of Verona
(Verona, Italy) and the University of Pisa (Pisa, Italy). This panel
included 36 PDAC and 16 AVC (see supplementary Table S1 for
detailed clinical information of cancer samples). The 23 PDAC
tumors were passaged in vitro as cell lines or in nude mice as
xenografts to remove contaminating non-neoplastic cells [25]. Cell
lines were harvested after a maximum of six in vitro passages for
nucleic acid preparation. Thirteen PDAC samples were previously
described human pancreatic tumour cell lines [26] (see supple-
mentary Table S2 for details). Tissue samples estimated to
contain more than 80% of tumour cells were used. Genomic DNA
was isolated using Dneasy Blood and Tissue kit (Qiagen, Milan,
Italy). Matched normal DNA was used to determine whether the
mutations identified were somatic or germline. No matched
normal sample was available for the 13 established cell lines
included in the study. Genomic DNA was further isolated after
cryostat enrichment from frozen tissues of primary PDAC to
confirm the mutations eventually identified in the corresponding
xenografted tumors.
Genes, PCR and Sequencing
Thirty-five genes belonging to the protein kinase gene family
were chosen on the basis of their high frequency of mutations in
human cancers other than pancreatic as assessed in previous works
[14–22]. These genes were: AKT2, ATM, ATR, AURKC, BRAF,
BRD2, DDR1, DYRK2, EGFR, EPHA3, EPHA5, EPHB6, EPHB2,
ERBB2, ERBB4, FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT3,
FRAP1, KDR, KIT, MAP2K4, MET, NTRK2, NTRK3, PAK4,
PDGFRA, PDPK1, PI3KCA, RPS6KC1, STK11, TGFBR2. Primers
for amplification and sequencing of DNA were designed using the
Primer3 program (http://frodo.wi.mit.edu/cgi-bin/primer3/
primer3_www.cgi) and refer to National Center for Biotechnology
Information (NCBI, http://www.ncbi.nlm.nih.gov) reference se-
quence files with the Gene and Transcript ID (RefSeq) provided in
supplementary Table S3. PCR primers were designed to amplify
the selected exons and the flanking intronic sequences, including
splicing donor and acceptor regions. PCR products were ,400 bp
in length, with multiple overlapping amplimers for larger exons.
PCR conditions, purification, and direct sequencing have been
previously described [14].
Data analysis
Sequence differences to the NCBI reference sequence were
identified via manual inspection of aligned electropherograms
assisted by the Mutation Surveyor software package (SoftGenetics,
State College, PA). The genetic alteration identified were cross-
referenced to variant information from the NCBI SNP database,
the Ensemble Genome Browser (http://www.ensembl.org), The
Swiss-Prot (http://ca.expasy.org) and GeneBank databases
http://www.ncbi.nlm.nih.gov/Genbank), the COSMIC database
(http://www.sanger.ac.uk/genetics/CGP/cosmic), and literature.
In addition to non-synonymous genetic alterations, we detected
numerous silent sequence variations that were analyzed using the
ASSP (http://www.es.embnet.org/,mwang/assp.html) sequence
analysis tool to exclude that cryptic splices sites may be activated.
These silent mutations are not presented and further analyzed
here. All new sequence data has been deposited in GenBank.
Results and Discussion
We performed a mutational profiling of 35 kinase genes in a
panel of 36 PDAC, and 16 AVC, including primary tumours,
xenografts and cell lines. For each gene, all exons in which somatic
mutation had been previously identified were analyzed. Exon
specific primers were designed to amplify and sequence the coding
region, and at least 15 intronic bases at both the 59 and 39 ends,
including the splicing donor and acceptor sites. A total of 8,321
PCR products, spanning over 3 Mb of tumour genomic DNA,
were generated and subjected to direct sequencing. Of the 147
exons extracted, 92% furnished good sequence traces (i.e., more
than 90% of bases in the target region had a Phred score (defined
as 210[log10(raw per-base error)]) of at least 20 in at least three-
quarters of the samples analyzed), and therefore were analyzed
searching for specific mutations. Changes previously described as
single nucleotide polymorphisms (SNPs) were excluded from
further analysis. To ensure that the eventually observed mutations
were not PCR or sequencing artifacts, amplicons were indepen-
dently re-amplified and re-sequenced in the corresponding
tumours. All verified changes were resequenced in parallel with
the matched normal DNA, to distinguish between somatic
mutations and SNPs not previously described.
This approach led to the identification of a total of 10 different
non-synonymous mutations (Table 1). Among these mutations, 9
were missense; one was a small insertion, whilst no mutations were
found in the splice sites or UTR regions (Table 1).
With regard to PDAC we analyzed a total of 36 samples, 13 of
which were established cell lines. A total of 7 different missense
mutations affecting the following genes were found: BRAF, EGFR,
EPHA3, EPHB2, FGFR2, KIT, PIK3CA (Table 1). Of these
mutations FGFR2
P582L and PIK3CA
H1047R were identified in
adenocarcinoma cell lines (PT45 and GER, respectively) for
which no matched normal sample was available. Therefore, the
somatic status of these mutations could not be ascertained. The
PIK3CA
H1047R mutation has been previously related to cancer and
extensively characterized [27–30]. Although mutations of FGFR2
have been previously found in human cancers [16,31,32], no
mutations of this gene have been reported to be associated with
pancreatic cancers to date. Our characterization of established
pancreatic tumour cell lines with the respect to the genetic
alterations in this potential cancer target family finally provides
suitable cell systems for data interpretation, target validation, as
well as preclinical models for the development of novel targeted
cancer drugs. BRAF
G464V has been previously related to cancer
and characterized [33]. The finding of a BRAF mutation in PDAC
is somehow expected since its related pathway is altered in almost
all the pancreatic adenocarcinomas [34], although individual
BRAF mutations are quite infrequent in this type of cancer and
generally occur in tumours that lack KRAS mutations [35,36].
Interestingly, the mutation we found was in homozygous state
(Figure 1B), which is not expected for a protein that acts in a
dominant fashion. The same missense somatic mutations of
EPHB2 (D283H) were found in two different PDAC samples
(Figure 1A), one of which also displayed a missense mutation in
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were re-analyzed in the corresponding primary tumours (Supple-
mentary Figure S1) to further confirm the presence of mutations
and thus exclude the possibility that the genetic alterations could
be the consequence of the graft in nude mice. In particular, the
sequencing analysis of the primary cancer corresponding to
xenograft 377 (Table 1) also confirmed the homozygous state of
the mutation identified in the BRAF gene. The Eph receptors
represent the largest subfamily of trans-membrane tyrosine kinase
receptors and are primary involved in the process of cell adhesion
and migration during development, homeostasis and disease
[13,37]. In this study, we report the mutational profile of four
members of this family (EPHA3, EPHA7, EPHB2, and EPHB6),
which have been found frequently mutated or silenced in previous
study on human cancers [13]. For example, mutations of EPHB2
that presumably lead to a loss of activity have been found in
colorectal and prostate cancer [38,39], whilst mutations in EPHA3
have been described in melanoma, lung and colorectal cancer
[14–16,19]. Thus far, no mutations of EPHB2 have been reported
to be associated with pancreatic cancer. Otherwise, a very recent
work that deeply analyzed the protein-coding genes in pancreatic
adenocarcinomas reported the occurrence of an intronic point
mutation of EPHA3 [34]. The mutations of EPHB2 and EPHA3
we found in this study localized in the evolutionary conserved Cys-
rich extracellular domain that is thought to be involved in
determining the binding affinity to their ligands as well as the
tetramerization of activated receptors [40]. Indeed, these aminoa-
cid changes (D283H and K207N) may affect the binding of the
receptors to their ligands and therefore possibly disrupt the normal
signalling cascade. Furthermore, increasing evidence suggest a role
of ephrin receptor/ephrin system in invasiveness in cancer as well
as its potential relevance for therapeutic targeting [41]. Mutations
of EGFR (L815F) affecting the kinase domain was harboured in
only one of the PDAC samples according to the low incidence of
EGFR somatic alterations found in pancreatic cancer by others
[42,43]. Finally, we report for the first time a somatic mutation in
the kinase domain of KIT (R740K) in PDAC cancer. KIT, also
designated as CD117, is frequently affected by activating mutations
in gastro-intestinal stromal tumours [44,45], thus representing a
logical therapeutic target for this malignancy [46]. Although
several studies suggest an involvement of KIT in pancreatic
carcinogenesis, no somatic mutations have been previously found
[47–49].
Concerning AVC we analyzed a total of 16 samples, including
15 primary tumours and one cell line. We found a total of four
different somatic mutations, of which three were missense and one
was a small insertion, affecting the following genes (Table 1): ATM,
EGFR, EPHA3, and ERBB2. The somatic mutation ERBB2
V777L
has been previously found in human cancers [50,51]. Further-
more, a careful analysis of ERBB2 sequence electropherogram
showed that the peak corresponding to the mutation was minor as
compared to its wild type counterpart (Figure 1C). This suggest
the occurrence of this variant only in a subpopulation of tumour
cells of the samples. One of the most interesting alterations we
found was the insertion occurring in the exon 22 of EGFR that
leads to a premature stop codon at aminoacid 896 within the
catalytic domain of the protein. This mutation however needs
further evaluation to determine its functional significance.
Interestingly, the EPHA3
K207N mutation has also been detected
in a PDAC sample. This possibly suggests a partial overlapping
spectrum of genetic alteration underlying these different pancre-
atic cancer subtypes unless these are mutations occurring by
chance.
In conclusion, in this study we identified 10 different mutations
affecting 9 kinase genes in pancreatic ductal adenocarcinoma and
ampulla of Vater cancers. No definite pattern of somatic mutations
was identified for each tumour types and only one alteration
(EPHA3
K207N) showed overlap between the tumor types analyzed.
In agreement with the results from previous studies we observed a
low frequency of specific somatic mutations in kinase genes
[15,16,18–22,34]. Except for the FGFR2 and PIK3CA mutations
that affected human tumour cell lines, the remaining 8 mutations
were found in samples derived from primary tumours and were
somatic in origin as assessed by the sequencing of the matched
Table 1. Mutations Indentified in Protein Kinase Genes.
Gene Nucleotide Change
a Amino acid change
a Mutation Type Zygosity
c Tumor Type
d Sample
ATM c.2879 C.T p.R823C Missense Heterozygous AVC 107p
BRAF c.1452 G.T p.G464V Missense Homozygous PDAC 377
EGFR c.2689 C.T p.L815F Missense Heterozygous PDAC 369
EGFR g.173783-173784insA 892fs896stop
b Insertion Heterozygous AVC 160p
EPHA3 c.846 G.T p.K207N Missense Heterozygous PDAC 549
EPHA3 c.846 G.T p.K207N Missense Heterozygous AVC 135p
EPHB2 c.865 G.C p.D283H Missense Heterozygous PDAC 549
EPHB2 c.865 G.C p.D283H Missense Heterozygous PDAC 370
ERBB2 c.2759 G.T p.V777L Missense Heterozygous AVC 119p
FGFR2 c.2337 C.T p.P582L Missense n.d. PDAC PT45
KIT c.2240 G.A p.R740K Missense Heterozygous PDAC PP161
PI3KCA c.3297 A.G p.H1047R Missense n.d. PDAC GER
NOTE: The mutations are listed by gene alongside the samples in which they were found. The nucleotide numbering uses the A of the ATG translation initiation start site
as nucleotide + 1, based on reference sequences provided in Supplementary Table S3.
ac., cDNA sequence; g., genomic sequence; ins, insertion; p., protein sequence; fs, frameshift mutation.
bThe insertion of the nucleotide A causes a frameshift and leads to a premature stop codon at amino acid 896.
cn.d., not determined.
dAVC, ampulla of Vater cancer; PDAC, pancreatic ductal adenocarcinoma.
eThe genetic alteration identified were cross-referenced with variant information from databases and literature (see Materials and Methods section for details).
doi:10.1371/journal.pone.0012653.t001
Kinases in Pancreatic Tumors
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Jones et al. performed a comprehensive genetic analysis leading to
the identification of a defined set of partially overlapping signalling
pathways that were altered, despite the fact that the alterations
affecting the individual component varied widely between
individual tumours [34]. Indeed, none of the somatic mutations
described by Jones et al were found in our analyses and viceversa.
Our and previous results thus suggest that a deep genetic analysis
for each gene could be performed in a large series of pancreatic
ductal adenocarcinoma samples to unravel the contribution of a
specific gene to pancreatic tumorigenesis.
Finally, none of the alterations we found in primary tumours
were previously described in cancers. These alterations require
further experimental evaluation to determine their functional
relevance and in some cases may turn out to represent passenger
rather than driver mutations. On the other hand, the localization
within defined protein domains indicates functional relevance of
most of the genetic alterations identified. Moreover, the mutations
affect genes that are potentially relevant as target of pharmacologic
intervention for these types of cancers. It is the case of the most
promising alterations we found affecting the EPHA3 and EPHB2
genes in pancreatic adenocarcinoma and AVC samples, consid-
ering their emerging role as attractive therapeutic target in cancer
[41].
Supporting Information
Figure S1 Examples of somatic mutations identified in primary
PDAC samples. The chromatograms refer to the sequence of
tumor samples. A, homozygous mutation in BRAF (g.143148
G.T, p.G464V). B, heterozygous mutation in EPHB2 (g.152108
G.C, p.D283H). Arrows indicate the location of missense
mutation. Numbers above the sequence traces are part of the
software output. The nucleotide numbering uses the A of the ATG
translation initiation start site as nucleotide +1, based on reference
sequences provided in Supplementary Table S3.
Found at: doi:10.1371/journal.pone.0012653.s001 (1.35 MB TIF)
Table S1 Clinical information on the pancreatic tumours
included in the study.
Found at: doi:10.1371/journal.pone.0012653.s002 (0.06 MB
DOC)
Table S2 Pancreatic tumor cell lines included in this study.
Found at: doi:10.1371/journal.pone.0012653.s003 (0.03 MB
DOC)
Table S3 Protein kinase genes and primers used for PCR
amplification and sequencing.
Found at: doi:10.1371/journal.pone.0012653.s004 (0.24 MB
DOC)
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